Bio/Pharma Business

Boehringer Ingelheim has signed an option to acquire Trutino Biosciences.

Roche has received approval from the European Commission for Lunsumio (mosunetuzumab), the first CD20xCD3 T-cell engaging bispecific antibody for treating follicular lymphoma.

The acquisition grants Bristol Myers Squibb access to the company's oncology pipeline and lead candidate, repotrectinib.

Sanofi will grant Regeneron worldwide exclusive license rights to Libtayo, a treatment for non-small cell lung cancer.

Astellas and GO Therapeutics will work together to develop novel antibodies for immuno-oncology.

Cambrex’s acquisition of Q1 Scientific expands the company’s storage services in the European market.

Is AI a panacea for pharma’s productivity gap?

Precompetitive consortiums seek solutions to industry-wide challenges.

GSK’s acquisition of Affinivax will give the company access to their portfolio of next-generation pneumococcal vaccines.

Through the Thermo Fisher Scientific and LabShares Newton partnership, life science startups can accelerate early-stage discovery and development with shared lab spaces.

Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.

AbbVie and Cugene have reached an exclusive license option agreement for CUG252, Cugene’s lead therapeutic candidate.

Sferalp will use Fluid Air’s PolarDry technology for powder processing.

AstraZeneca has signed a license agreement with RQ Biotechnology for monoclonal antibodies to treat COVID-19.

Pfizer will acquire Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in migraine treatments, for $11.7 billion.

Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.

GeoVax has received a patent for its malaria vaccine from the US Patent and Trademark Office.

Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.

GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9 billion.

Ymmunobio AG has signed a patent purchase agreement with LeukoCom GmbH to expand its development of cancer therapies.

Pfizer plans to acquire ReViral and its respiratory syncytial virus therapeutic candidates to strengthen Pfizer’s capabilities in infectious disease research.

Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.

Standardization is needed in CAR-T cell therapy development due to its inherent complexity.

Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.

Consumer advocates continue to press for initiatives to lower drug prices by revising or reducing patent protections.

Teva has reached an agreement with the Attorney General of Rhode Island to settle opioid-related claims.

Emmes has acquired Casimir, marking its fourth major acquisition.

The US Congress approved a federal spending package that increases funding for a range of programs to advance health and medicine.

Biotech companies and medical product manufacturers have condemned the invasion of Ukraine, while also looking to maintain supplies of essential medicines.

Novartis will pay Voyager up to $1.75 billion for access to Voyager’s novel Tracer AAV capsids for potential use with three CNS targets.